Abstract
Autoimmune neuropathy is a distinct subclass of immune-mediated neuropathy with a unique antibody-mediated profile. Early recognition is crucial for relief from the symptoms. The aim of this report was to highlight the clinical presentation and diagnostic and therapeutic challenges in a case of anti-neurofascin 186 nodopathy. A 46-year-old woman presented with progressive weakness in the lower limbs and pain in the palms and soles lasting for two years. She failed to respond to intravenous immunoglobulin and tapering steroids. Later, she was started on rituximab and showed significant neurological improvement over time. The findings indicate that early antibody testing can guide the effective management of autoimmune nodopathy.